VF
SXTC icon

Virtu Financial’s China SXT Pharmaceuticals SXTC Stock Holding History

Virtu Financial’s Portfolio SXTC Stock Details SXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-82
Closed -$20K – 2284
2025
Q4 		$20K Sell
82
-111
-58% -$24.1K ﹤0.01% 1429
2025
Q3 		$46K Buy
193
+100
+108% +$24.7K ﹤0.01% 1147
2025
Q2 		$24K Buy
+93
New +$26.4K ﹤0.01% 1238
2024
Q3 		– Sell
-26
Closed -$34K – 1867
2024
Q2 		$34K Buy
+26
New +$36.9K ﹤0.01% 959
2023
Q2 		– Sell
-1
Closed -$11K – 2018
2023
Q1 		$11K Sell
1
-2
-67% -$26.9K ﹤0.01% 1339
2022
Q4 		$48K Buy
+3
New +$57.6K 0.01% 1093
2022
Q3 		– Hold
0
– -$26K – 2224
2022
Q2 		– Hold
0
– – – 1279
2022
Q1 		– Hold
0
– – – 1265
2021
Q4 		– Hold
0
– – – 1463
2021
Q3 		– Hold
0
– – – 1307
2020
Q4 		– Hold
0
– -$5K – 1778
2020
Q3 		– Hold
0
– – – 970
2019
Q2 		– Hold
0
– -$182K – 1852
2019
Q1 		– Hold
0
– – – 1027

Other funds holding SXTC

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Virtu Financial's SXTC Position: Q1 2026 in Review

Virtu Financial sold out of China SXT Pharmaceuticals (SXTC) in Q1 2026, closing a stake of 82 shares — an estimated $20K sold.

Virtu Financial first reported a position in SXTC in Q4 2022 and held it in 6 quarters. The position peaked at $48K in Q4 2022. 4 funds tracked by Wall St. Rank hold SXTC as of Q1 2026.

  • Virtu Financial reported no remaining China SXT Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Virtu Financial sold 82 China SXT Pharmaceuticals shares in Q1 2026, an estimated $20K.
  • Virtu Financial first reported a position in China SXT Pharmaceuticals in Q4 2022 and held it in 6 quarters.
  • Virtu Financial's China SXT Pharmaceuticals position peaked at $48K in Q4 2022.
  • 4 funds tracked by Wall St. Rank held China SXT Pharmaceuticals as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.